Myelodysplastic Syndrome - Pipeline Review, H2 2016

Date: November 30, 2016
Pages: 749
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MC7C49AFDC5EN
Leaflet:

Download PDF Leaflet

Myelodysplastic Syndrome - Pipeline Review, H2 2016
Myelodysplastic Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome – Pipeline Review, H2 2016, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11, 62, 55, 3, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 6, 7, 2, 1 and 2 molecules, respectively.Myelodysplastic Syndrome.

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Myelodysplastic Syndrome Overview
Therapeutics Development
Myelodysplastic Syndrome - Therapeutics under Development by Companies
Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes
Myelodysplastic Syndrome - Pipeline Products Glance
Myelodysplastic Syndrome - Products under Development by Companies
Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
Myelodysplastic Syndrome - Therapeutics Assessment
Drug Profiles
Myelodysplastic Syndrome - Dormant Projects
Myelodysplastic Syndrome - Discontinued Products
Myelodysplastic Syndrome - Product Development Milestones
Appendix 730

LIST OF TABLES

Number of Products under Development for Myelodysplastic Syndrome, H2 2016
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Investigation by Universities/Institutes, H2 2016
Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2016
Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Aileron Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Altor BioScience Corp, H2 2016
Myelodysplastic Syndrome - Pipeline by Amgen Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H2 2016
Myelodysplastic Syndrome - Pipeline by Ariad Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Arno Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Arog Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by BerGenBio AS, H2 2016
Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by BioLineRx Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by BioLite Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Myelodysplastic Syndrome - Pipeline by Boston Biomedical Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2016
Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Celgene Corp, H2 2016
Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Celyad SA, H2 2016
Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by CrystalGenomics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp, H2 2016
Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by DiNonA Inc., H2 2016
Myelodysplastic Syndrome - Pipeline by Eisai Co Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by Eleos Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H2 2016
Myelodysplastic Syndrome - Pipeline by EpiZyme Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by FORMA Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Fujifilm Corp, H2 2016
Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by IGF Oncology LLC, H2 2016
Myelodysplastic Syndrome - Pipeline by ImmunoGen Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Incyte Corp, H2 2016
Myelodysplastic Syndrome - Pipeline by Io Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Jazz Pharmaceuticals Plc, H2 2016
Myelodysplastic Syndrome - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H2 2016
Myelodysplastic Syndrome - Pipeline by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., H2 2016
Myelodysplastic Syndrome - Pipeline by Juno Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corp, H2 2016
Myelodysplastic Syndrome - Pipeline by Kainos Medicine Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Kiadis Pharma NV, H2 2016
Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by La Jolla Pharmaceutical Company, H2 2016
Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by MacroGenics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Mateon Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by medac GmbH, H2 2016
Myelodysplastic Syndrome - Pipeline by MedImmune LLC, H2 2016
Myelodysplastic Syndrome - Pipeline by MEI Pharma Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Merck & Co Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Merus NV, H2 2016
Myelodysplastic Syndrome - Pipeline by Mesoblast Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Nemucore Medical Innovations Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Novartis AG, H2 2016
Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by OncoTherapy Science Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by Pfizer Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Pharma Mar SA, H2 2016
Myelodysplastic Syndrome - Pipeline by Regen BioPharma Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Seattle Genetics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Takara Bio Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by Targazyme Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H2 2016
Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
Myelodysplastic Syndrome - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2016
Myelodysplastic Syndrome - Pipeline by Tolero Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Tragara Pharmaceuticals Inc, H2 2016
Myelodysplastic Syndrome - Pipeline by Trillium Therapeutics Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Myelodysplastic Syndrome - Dormant Projects, H2 2016
Myelodysplastic Syndrome - Dormant Projects (Contd..1), H2 2016
Myelodysplastic Syndrome - Dormant Projects (Contd..2), H2 2016
Myelodysplastic Syndrome - Dormant Projects (Contd..3), H2 2016
Myelodysplastic Syndrome - Dormant Projects (Contd..4), H2 2016
Myelodysplastic Syndrome - Dormant Projects (Contd..5), H2 2016
Myelodysplastic Syndrome - Dormant Projects (Contd..6), H2 2016
Myelodysplastic Syndrome - Discontinued Products, H2 2016
Myelodysplastic Syndrome - Discontinued Products (Contd..1), H2 2016 735

LIST OF FIGURES

Number of Products under Development for Myelodysplastic Syndrome, H2 2016
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Premenstrual Syndrome - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 41 pages
Fragile X Syndrome - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 95 pages
Premenstrual Syndrome - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 38 pages
Sjogren's Syndrome - Pipeline Review, H1 2015 US$ 1,600.00 May, 2015 · 63 pages
Polycystic Ovarian Syndrome - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 54 pages

Ask Your Question

Myelodysplastic Syndrome - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: